Benefit-Risk And Medical Costs of Rivaroxaban 20mg Versus Vitamin K Antagonists From A French Nationwide Cohort of 220,000 Patients With Non-Valvular Atrial Fibrillation
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.1192
https://www.valueinhealthjournal.com/article/S1098-3015(17)31526-7/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1138
First Page :
A608
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31526-7&doi=10.1016/j.jval.2017.08.1192